To provide an updated overview of acute myeloid leukemia (AML), including its incidence, pathogenesis, clinical manifestations, diagnosis, classification, and the importance of personalized treatment approaches based on genetic and molecular characteristics.
Key Findings:
AML incidence is higher in older adults, with poor prognosis in those over 65.
Genetic mutations are present in over 97% of AML cases, influencing pathogenesis and prognosis.
The WHO classification system incorporates genetic data for more precise diagnosis and treatment.
Age significantly impacts prognosis, particularly in patients over 65.
Interpretation:
The complexity of AML's pathogenesis and classification underscores the need for personalized treatment approaches based on genetic and molecular characteristics.
Limitations:
Further research is needed to fully understand the contributions of individual mutations to AML development.
Current classification systems may not encompass all genetic variations and their clinical implications, highlighting the need for more comprehensive systems.
Conclusion:
AML remains a challenging disease with significant advancements in understanding its biology and classification, yet many aspects require further exploration for improved patient outcomes, emphasizing the urgency for continued research.
